

# Obesity & Metabolic Intelligence Report

GLP-1 · GIP · MASH · NASH · Cardiometabolic · Vision 2030

● **LIVE INGEST**

Last refresh — 07 May 2026 21:44:40Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <h1>1,679</h1> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <h1>4 / 6</h1> <p>Of 6 wired</p>	<p>COMPANIES MONITORED</p> <h1>50</h1> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH</p> <h1>144</h1> <p>Material signals (90d)</p>
---	--	---	---

**RISK REGISTER · THE COST OF SEEING LATE** Adversarial verification scope

## Three exposures every metabolic portfolio carries today.

---

**Reimbursement Cycle Risk**

GLP-1, GIP, and MASH coverage decisions in flight across the 2025–2026 cycle reshape roughly \$80B in run-rate exposure. Live PubMed and formulary signals are tracked across the indexer.

### 1,000

---

**MASH First-in-Class Risk**

Madrigal's resmetirom approval cracked open MASH as a first-in-class category. Akero, Viking, and 89bio Phase 3 readouts will reshape adjacent cardiometabolic positioning. Material signals across the MASH and NASH frontier are tracked.

### 9

---

**Sovereign Procurement Risk**

KSA, GCC, and MENA metabolic manufacturers under continuous monitoring. Vision 2030 cardiometabolic procurement windows close on a tender cycle — missing one means missing a generation.

### 5 / 50

## What we are watching

FDA openFDA		333
ClinicalTrials.gov		196
PubMed		1000
SEC EDGAR		150
CMS LCD		0
USPTO Patents		0
Manufacturer Pipelines		0

## Top 10 by severity and recency

PUBMED CRITICAL 2026-05-06

**Does the Combination of Abdominal Obesity and Vitamin D Deficiency Increase the Risk of Death in Individuals Aged 50 or Older? Evidence From the ELSA Study.**

da Silva Milliati J

Does the Combination of Abdominal Obesity and Vitamin D Deficiency Increase the Risk of Death in Individuals Aged 5...

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-04-29

**SGLT2i combined with physical training attenuates metabolic dysfunction and pyroptosis-mediated renal cell death in diabetic kidney disease.**

Lass AD

SGLT2i combined with physical training attenuates metabolic dysfunction and pyroptosis-mediated renal cell death in...

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

**Fatal systemic AA amyloidosis with pulmonary Mycobacterium avium infection: an autopsy case report.**

Takahashi Y

Fatal systemic AA amyloidosis with pulmonary Mycobacterium avium infection: an autopsy case report.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

**Pulmonary mucormycosis with endobronchial involvement due to Rhizopus homothallicus: a fatal case report.**

Hernández-Solís A

Pulmonary mucormycosis with endobronchial involvement due to Rhizopus homothallicus: a fatal case report.

PubMed (NCBI E-utilities) ↗

PUBMED CRITICAL 2026-01-01

**Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City.**

Perezalonso-Espinosa J

Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a...

PubMed (NCBI E-utilities) ↗

FDA CRITICAL 2016-08-17

**HeartWare Ventricular Assist System (HVAD), US product: Model No.: 1103; and International Product: Model No.: 1104XX. Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter.**

HeartWare, Inc

Foreign material found within the driveline connector of the HVAD Pump that could cause increased impedance resultin...

U.S. Food & Drug Administration ↗

FDA CRITICAL 2016-06-08

**HeartWare Ventricular Assist System Controller Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HVAD is designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter**

Heartware, Inc.

Loose connector ports in controller body.

U.S. Food & Drug Administration ↗

FDA CRITICAL 2009-09-22

**Penumbra Neuron Delivery Catheter 070, percutaneous catheter, catalog numbers PND6F070I058, PND6F070956, PND6F070I058M, and PND6F070956M; manufactured by Penumbra, Inc., Alameda, CA. Indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.**

Penumbra Inc.

Failure-- product can kink or ovalize, which may result in difficulty in catheter advancement or delivery of other...

U.S. Food & Drug Administration ↗

PUBMED HIGH 2026-05-15

**Frailty status and mortality among patients with cardiometabolic diseases in an international multi-cohort study.**

Ren R

Frailty status and mortality among patients with cardiometabolic diseases in an international multi-cohort...

PubMed (NCBI E-utilities) ↗

SEC HIGH 2026-05-07

**LLY — 8-K filing**

LLY

8-K

SEC EDGAR ↗

## MASH & NASH watchlist

MASH FRONTIER · FIRST-IN-CLASS · 2025-2026

### Resmetirom opened MASH as a category. Akero, Viking, and 89bio Phase 3 readouts close the next window.

Madrigal's resmetirom is the first FDA-approved MASH therapy — a category that did not commercially exist twelve months ago. Akero (efruxifermin), Viking (VK2809 and VK2735 cardiometabolic adjacency), and 89bio (pegozafermin) Phase 3 readouts will reshape adjacent cardiometabolic and cardiovascular positioning. The risk window between trial readout and equity repricing is narrow. AimwellBio tracks every Phase 2 and Phase 3 protocol amendment, biopsy endpoint, MAESTRO-NASH-style readout, and FDA correspondence in the indexer.

## Saudi Arabia • Vision 2030

SOVEREIGN VECTOR • KSA / VISION 2030

### Saudi Arabia carries a structural diabetes-obesity burden. The Ministry of Health has positioned cardiometabolic disease as a Vision 2030 procurement priority.

SPIMACO Metabolic, Tabuk Metabolic, Julphar Metabolic, Hikma Metabolic, and Eva Pharma Metabolic anchor the GCC and MENA cardiometabolic supply surface. The cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's metabolic intelligence layer. SFDA approvals, MOH formulary movements, and cross-border GLP-1, GIP, and MASH infrastructure across Riyadh, Jeddah, Dubai, Abu Dhabi, Amman, and Cairo are already trackable through the indication-aware pipeline.

Decisions of this scale — coverage policy, capital procurement of GLP-1 supply, MASH access, and cardiometabolic prevention programs — cannot rest on a single vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.

~18%

KSA diabetes-obesity overlap

5 / 50

Sovereign-tagged manufacturers monitored

~\$80B

Global GLP-1 + GIP run-rate exposure

7

Public sources triangulated per signal class

SOVEREIGN ROSTER • KSA / GCC / MENA

<p><b>SPIMACO Metabolic</b></p> <p>Riyadh, SA</p> <p>KSA</p>	<p><b>Tabuk Metabolic</b></p> <p>Tabuk, SA</p> <p>KSA</p>	<p><b>Julphar Metabolic</b></p> <p>Ras Al Khaimah, AE</p> <p>GCC</p>	<p><b>Hikma Metabolic</b></p> <p>Amman, JO</p> <p>MENA</p>	<p><b>Eva Pharma Metabolic</b></p> <p>Cairo, EG</p> <p>MENA</p>
--	---	--	--	---

## Monitored issuers and operators


<p><b>Eva Pharma Metabolic</b> Cairo, EG</p> <p>MENA</p>	<p><b>Hikma Metabolic</b> HIK Amman, JO</p> <p>MENA</p>	<p><b>Julphar Metabolic</b> Ras Al Khaimah, AE</p> <p>GCC</p>
<p><b>SPIMACO Metabolic</b> Riyadh, SA</p> <p>KSA</p>	<p><b>Tabuk Metabolic</b> Tabuk, SA</p> <p>KSA</p>	<p><b>89bio</b> ETNB San Francisco, CA</p> <p>BIOTECH</p>
<p><b>Aardvark Therapeutics</b> San Diego, CA</p> <p>BIOTECH</p>	<p><b>Abbott Metabolic Diagnostics</b> ABT Alameda, CA</p> <p>MEDTECH</p>	<p><b>AbbVie Metabolic</b> ABBV North Chicago, IL</p> <p>BIGPHARMA</p>
<p><b>Akero Therapeutics</b> AKRO South SF, CA</p> <p>BIOTECH</p>	<p><b>Allurion Technologies</b> ALUR Natick, MA</p> <p>MEDTECH</p>	<p><b>Altimmune</b> ALT Gaithersburg, MD</p> <p>BIOTECH</p>
<p><b>Amgen MariTide</b> AMGN Thousand Oaks, CA</p> <p>BIGPHARMA</p>	<p><b>Apollo Endosurgery (Boston Scientific)</b> BSX Marlborough, MA</p> <p>MEDTECH</p>	<p><b>Aspen Metabolic</b> Durban, ZA</p> <p>BIGPHARMA</p>
<p><b>AstraZeneca Metabolic</b> AZN Cambridge, UK</p> <p>BIGPHARMA</p>	<p><b>BioAge Labs</b> BIOA Richmond, CA</p> <p>BIOTECH</p>	<p><b>Boehringer Ingelheim Metabolic</b> IngeLheim, DE</p> <p>BIGPHARMA</p>
<p><b>Calibrate</b> New York, NY</p> <p>EMERGING</p>	<p><b>Carmot Therapeutics</b> Berkeley, CA</p> <p>BIOTECH</p>	<p><b>Eli Lilly Obesity</b> LLY Indianapolis, IN</p> <p>BIGPHARMA</p>
<p><b>Found Health</b> San Francisco, CA</p> <p>EMERGING</p>	<p><b>Galmed Pharmaceuticals</b> GLMD Tel Aviv, IL</p> <p>BIOTECH</p>	<p><b>Hanmi Metabolic</b> Seoul, KR</p> <p>BIGPHARMA</p>
<p><b>Hims &amp; Hers Health</b> HIMS San Francisco, CA</p> <p>EMERGING</p>	<p><b>Hua Medicine</b> Shanghai, CN</p> <p>BIOTECH</p>	<p><b>Innovent Metabolic</b> Suzhou, CN</p> <p>BIOTECH</p>
<p><b>Inventiva</b> IVA Daix, FR</p> <p>BIOTECH</p>	<p><b>Madrigal Pharmaceuticals</b> MDGL Conshohocken, PA</p> <p>BIOTECH</p>	<p><b>Medtronic Bariatric</b> MDT Minneapolis, MN</p> <p>MEDTECH</p>

<b>Merck Metabolic</b> <b>MRK</b> Rahway, NJ <b>BIGPHARMA</b>	<b>Metsera</b> New York, NY <b>BIOTECH</b>	<b>Noom</b> New York, NY <b>EMERGING</b>
<b>Novo Nordisk Obesity</b> <b>NVO</b> Bagsvaerd, DK <b>BIGPHARMA</b>	<b>Olympus Endoscopy</b> Tokyo, JP <b>MEDTECH</b>	<b>Pfizer Obesity</b> <b>PFE</b> New York, NY <b>BIGPHARMA</b>
<b>ReShape Lifesciences</b> <b>RSLS</b> Irvine, CA <b>MEDTECH</b>	<b>Reverse Diabetes</b> Boston, MA <b>EMERGING</b>	<b>Ro (Roman)</b> New York, NY <b>EMERGING</b>
<b>Roche Metabolic</b> Basel, CH <b>BIGPHARMA</b>	<b>Roche Metabolic Diagnostics</b> Basel, CH <b>MEDTECH</b>	<b>Sanofi Metabolic</b> <b>SNY</b> Paris, FR <b>BIGPHARMA</b>
<b>Sequence (Weight Watchers)</b> <b>WW</b> New York, NY <b>EMERGING</b>	<b>Skye Bioscience</b> <b>SKYE</b> San Diego, CA <b>BIOTECH</b>	<b>Structure Therapeutics</b> <b>GPCR</b> South SF, CA <b>BIOTECH</b>
<b>Sun Pharma Metabolic</b> Mumbai, IN <b>BIGPHARMA</b>	<b>Terns Pharmaceuticals</b> <b>TERN</b> Foster City, CA <b>BIOTECH</b>	<b>Veru</b> <b>VERU</b> Miami, FL <b>BIOTECH</b>
<b>Viking Therapeutics</b> <b>VKTX</b> San Diego, CA <b>BIOTECH</b>	<b>WeightWatchers (WW)</b> <b>WW</b> New York, NY <b>EMERGING</b>	

06 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

## Volume & cadence of public disclosure



METHODOLOGY

This report is generated from a live ingest pipeline ( `tools/scout-ingest` ). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated 07 May 2026 21:44:40Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

**Confidence framework.** Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

**Limitations.** This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.